InvestorsHub Logo
Followers 199
Posts 17210
Boards Moderated 2
Alias Born 02/17/2012

Re: None

Tuesday, 07/27/2021 7:44:16 AM

Tuesday, July 27, 2021 7:44:16 AM

Post# of 5639
OCGN “Ocugen initiated with an Outperform at Noble Capital”

Noble Capital analyst Robert LeBoyer initiated coverage of Ocugen with an Outperform rating and $15 price target. The company has in-licensed Covaxin, a whole-virion vaccine for Covid-19 that has advantages over the the current vaccines in use today, LeBoyer tells investors in a research note.

https://m.thefly.com/news-story/3341723/2021-07-26%2010:00:13/search

What we've got here...is failure to communicate. Some men you just can't reach...which is the way he wants it, well, HE GETS IT! And I dont like it anymore than you men.

*Contact your licensed financial advisor before entering the market.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OCGN News